AIMS/HYPOTHESIS: Adipose tissue inflammation has recently been implicated in the pathogenesis of insulin resistance and is probably linked to high local levels of cytokines. IL1B, a proinflammatory cytokine, may participate in this alteration. MATERIALS AND METHODS: We evaluated the chronic effect (1-10 days) of IL1B (0.1-20 ng/ml) on insulin signalling in differentiating 3T3-F442A and differentiated 3T3-L1 murine adipocytes and in human adipocytes. We also assessed expression of the gene encoding IL1B in adipose tissue of wild-type and insulin-resistant mice (diet-induced and genetically obese ob/ob mice). RESULTS: IL1B inhibited insulin-induced phosphorylation of the insulin receptor beta subunit, insulin receptor substrate 1, Akt/protein kinase B and extracellular regulated kinase 1/2 in murine and human adipocytes. Accordingly, IL1B suppressed insulin-induced glucose transport and lipogenesis. Long-term treatment of adipose cells with IL1B decreased cellular lipid content. This could result from enhanced lipolysis and/or decreased expression of genes involved in lipid metabolism (acetyl-CoA carboxylase, fatty acid synthase). Down-regulation of peroxisome proliferating-activated receptor gamma and CCAAT/enhancer-binding protein alpha in response to IL1B may have contributed to the altered phenotype of IL1B-treated adipocytes. Moreover, IL1B altered adipocyte differentiation status in long-term cultures. IL1B also decreased the production of adiponectin, an adipocyte-specific protein that plays a positive role in insulin sensitivity. Expression of the gene encoding IL1B was increased in epididymal adipose tissue of obese insulin-resistant mice. CONCLUSIONS/ INTERPRETATION: IL1B is upregulated in adipose tissue of obese and insulin-resistant mouse models and may play an important role in the development of insulin resistance in murine and human adipose cells.
AIMS/HYPOTHESIS: Adipose tissue inflammation has recently been implicated in the pathogenesis of insulin resistance and is probably linked to high local levels of cytokines. IL1B, a proinflammatory cytokine, may participate in this alteration. MATERIALS AND METHODS: We evaluated the chronic effect (1-10 days) of IL1B (0.1-20 ng/ml) on insulin signalling in differentiating 3T3-F442A and differentiated 3T3-L1 murine adipocytes and in human adipocytes. We also assessed expression of the gene encoding IL1B in adipose tissue of wild-type and insulin-resistant mice (diet-induced and genetically obese ob/ob mice). RESULTS:IL1B inhibited insulin-induced phosphorylation of the insulin receptor beta subunit, insulin receptor substrate 1, Akt/protein kinase B and extracellular regulated kinase 1/2 in murine and human adipocytes. Accordingly, IL1B suppressed insulin-induced glucose transport and lipogenesis. Long-term treatment of adipose cells with IL1B decreased cellular lipid content. This could result from enhanced lipolysis and/or decreased expression of genes involved in lipid metabolism (acetyl-CoA carboxylase, fatty acid synthase). Down-regulation of peroxisome proliferating-activated receptor gamma and CCAAT/enhancer-binding protein alpha in response to IL1B may have contributed to the altered phenotype of IL1B-treated adipocytes. Moreover, IL1B altered adipocyte differentiation status in long-term cultures. IL1B also decreased the production of adiponectin, an adipocyte-specific protein that plays a positive role in insulin sensitivity. Expression of the gene encoding IL1B was increased in epididymal adipose tissue of obese insulin-resistant mice. CONCLUSIONS/ INTERPRETATION:IL1B is upregulated in adipose tissue of obese and insulin-resistant mouse models and may play an important role in the development of insulin resistance in murine and human adipose cells.
Authors: E Somm; P Cettour-Rose; C Asensio; A Charollais; M Klein; C Theander-Carrillo; C E Juge-Aubry; J-M Dayer; M J H Nicklin; P Meda; F Rohner-Jeanrenaud; C A Meier Journal: Diabetologia Date: 2005-12-30 Impact factor: 10.122
Authors: Aina S Lihn; Jens M Bruun; Gengsheng He; Steen B Pedersen; Peter F Jensen; Bjørn Richelsen Journal: Mol Cell Endocrinol Date: 2004-04-30 Impact factor: 4.102
Authors: Akshaya K Meher; Poonam R Sharma; Vitor A Lira; Masayuki Yamamoto; Thomas W Kensler; Zhen Yan; Norbert Leitinger Journal: Free Radic Biol Med Date: 2012-02-24 Impact factor: 7.376
Authors: Arijeet K Gattu; Andreas L Birkenfeld; Yasuko Iwakiri; Steven Jay; Mark Saltzman; Jennifer Doll; Petr Protiva; Varman T Samuel; Susan E Crawford; Chuhan Chung Journal: Endocrinology Date: 2014-01-23 Impact factor: 4.736
Authors: J de Castro; J Sevillano; J Marciniak; R Rodriguez; C González-Martín; M Viana; O H Eun-suk; S Hauguel de Mouzon; E Herrera; M P Ramos Journal: Endocrinology Date: 2011-09-13 Impact factor: 4.736
Authors: Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman Journal: Nature Date: 2010-07-22 Impact factor: 49.962
Authors: Robert Kleemann; Marjan van Erk; Lars Verschuren; Anita M van den Hoek; Maud Koek; Peter Y Wielinga; Annie Jie; Linette Pellis; Ivana Bobeldijk-Pastorova; Thomas Kelder; Karin Toet; Suzan Wopereis; Nicole Cnubben; Chris Evelo; Ben van Ommen; Teake Kooistra Journal: PLoS One Date: 2010-01-21 Impact factor: 3.240